Telix doses first patient in Phase 3 ProstACT GLOBAL study of TLX591
ProstACT GLOBAL is the first late-stage study to assess TLX591 in adult patients with PSMA-positive metastatic castrate-resistant prostate…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Nov 23
ProstACT GLOBAL is the first late-stage study to assess TLX591 in adult patients with PSMA-positive metastatic castrate-resistant prostate…
13 Nov 23
The approval was based on the results from two successful randomised, double-blind, active-controlled, multicentre Phase 3 trials which…
13 Nov 23
Both companies aim to expand their collaboration to cover the entire project, including the development, production, and clinical…
13 Nov 23
Trial expected to reach the primary endpoint of progression free survival in the second half of 2025
13 Nov 23
Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines
10 Nov 23
AstraZeneca will obtain exclusive rights to develop and commercialise Eccogene’s ECC5004 for all indications across the world, excluding…
10 Nov 23
The partnership will combine Recursion’s artificial intelligence (AI)-guided drug discovery platform with Bayer’s small molecule compound library and…
10 Nov 23
The approval was based on the totality of the evidence provided by the analysis of efficacy, pharmacokinetic, safety…
10 Nov 23
The approval was based on the findings from the QuANTUM-First trial in which the Vanflyta combination showed a…
10 Nov 23
In these studies, remibrutinib achieved all primary and secondary endpoints at Week 12 and the results showed that…